Ultragenyx acquires option to buy gene therapy firm

16 August 2019
ultragenyx_large

Ultra-rare disease specialist Ultragenyx Pharmaceutical (Nasdaq: RARE) has inked a deal with GeneTx Biotherapeutics in relation to the antisense oligonucleotide GTX-102.

The firms have agreed to collaborate on the development of GTX-102, which is designed to suppress the expression of the UBE3A-AS gene, as a possible treatment for Angelman syndrome.

Ultragenyx will make an upfront payment of $20 million for an exclusive option to acquire GeneTx, any time prior to 30 days after the Food and Drug Administration accepts an investigational new drug (IND) for GTX-102. The option period can be extended for an additional $25 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology